Treatment of Cutaneous T-Cell Lymphoma from a Dermatologist's Perspective

Clinical Lymphoma

Volumn 1, Issue 1 SUPPL., 2000, Pages

  Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

DAB389IL 2; Interferon; Lymphoma; Phototherapy; Retinoids; Rexinoid

Indexed keywords

CUTANEOUS T CELL LYMPHOMA; DERMATOLOGY; HUMAN; REVIEW; SKIN TUMOR;

DERMATOLOGY; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS;

EID: 0002602823     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.s.003     Document Type: Article

References (56)

1. Wood GS,Tung RM, Haeffner AC, et al. Detection of clonalT-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol 1994; 103:34-41.
2. Zelickson BD, Peters MS, Muller SA, et al. T-cell receptor gene rearrangement analysis: cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders. J Am Acad Dermatol 1991; 25:787-796.
3. Weinstock MA, Horm JW, Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 1988; 260:42-46.
4. Weinstock MA, Reynes JF. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer 1999; 85:208-212.
5. Joly P,Thomine E, Lauret P. Cutaneous lymphomas other than mycosis fungoides. Semin Dermatol 1994; 13:172-179.
6. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993; 28:973-980.
7. Jackow CM, McHam JB, Friss A, et al. HLA-DR5 and DQB 1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol 1996; 107:373-376.
8. Duvic M, Welsh EA, Jackow C, et al. Analysis of HLA-D locus alleles in alopecia areata patients and families. J Invest Dermatol 1995; 104:5S-6S.
9. Fuhlbrigge RC, Kieffer JD, Armerding D, et al. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997; 389:978-981.
10. Sarris AH, Esgleyes-Ribot T, Crow M, et al. Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? Blood 1995; 86:651-658.
11. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet 1986; 1:1466-1468.
12. Bunn PA Jr., Huffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994; 121:592-602.
13. Vowels BR, Cassin M, Vonderheid EC, et al. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992; 99:90-94.
14. Daliani D, Ulmer RA, Jackow C, et al. Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferoninducible protein-10. Leuk Lymphoma 1998; 29:315-328.
15. Jackow CM, Gather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood 1997; 89:32-40.
16. Leung DY, Harbeck R, Bina P, et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 1993; 92:1374-1380.
17. Leung DY, Walsh P, Giorno R, et al. A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol 1993; 100:225-228.
18. Leung DY, Travers JB, Norris DA. The role of superantigens in skin disease. J Invest Dermatol 1995; 105:37S-42S.
19. Kaye FJ, Bunn PA Jr., Steinberg SM. et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321:1784-1790.
20. Kim YH, Chow S, Varghese A, et al. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135:26-32.
21. Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1031-1056.
22. Chinn DM, Chow S, Kim YH, et al. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 1999; 43:951-958.
23. Zackheim HS, Epstein EH Jr. Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies. Arch Dermatol 1975; 111: 1564-1570.
24. Kuzel T, Breneman D, Duvic M, et al. Phase I-II trial of Targretin gel for the skin-directed topical treatment of patients with cutaneous T-cell lymphoma. J Invest Dermatol 2000; 114:4 (Abstract #536).
25. Conry RM, Bantia S, Turner HS, et al. Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells. Immunopharmacology 1998; 40:1-9.
26. Fox FE, Niu Z, Tobia A, et al. Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. J Invest Dermatol 1998; 111:327-332.
27. Zackheim H. Ultraviolet radiation and cutaneous lymphoma. Br J Cancer 1998; 78:1397-1398.
28. Watson A. Photochemotherapy for mycosis fungoides: current status. Australos J Dermatol 1997; 38:9-11.
29. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA).The PUVA Follow-Up Study. N Engal J Med 1997; 336:1041-1045.
30. Kuzel TM, Roenigk HH Jr., Samuelson E, et al. Effectiveness of Interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995; 13:257-263.
31. Krueger JG, Wolfe JT, Nabeya RT, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995; 182:2057-2068.
32. Wang XM, McNiff JM, Klump V, et al. An unexpected spectrum of p53 mutations from squamous cell carcinomas in psoriasis patients treated with PUVA. Photochem Photobiol 1997; 66:294-299.
33. Lauritzen AF, Vejlsgaard GL, Hou-Jensen K, et al. p53 protein expression in cutaneous T-cell lymphomas. Br J Dermatol 1995; 133:32-36.
34. McGregor JM, Dublin EA, Levison DA, et al. p53 immunoreactivity is uncommon in primary cutaneous lymphoma. Br J Dermatol 1995; 132:353-358.
35. Rook AH, Wolfe JT. Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. J Clin Apheresis 1994; 9:28-30.
36. Zic JA, Miller JL, Stricklin GP, et al. The North American experience with photopheresis. Ther Apher 1999; 3:50-62.
37. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35:573-579.
38. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant Interferon alfa: a 10-year experience at a single institution. J Am Acad Dermotol 1996; 35:946-957.
39. Rook AH, Suchin KR, Kao DM, et al. Photopheresis: clinical applications and mechanism of action. J Investig Dermatol Symp Proc 1999; 4:85-90.
40. Vonderheid EC, Bigler RD, Greenberg AS, et al. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response. Am J Clin Oncol 1994; 17:255-263.
41. Wilson LD, Licata AL, Braverman IM, et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radial Oncol Biol Phys 1995; 32:987-995.
42. Tokura Y, Yagi H, Ohshima A, et al. Cutaneous colonization with staphylococci influences the disease activity of Sezary syndrome: a potential role for bacterial superantigens. Br J Dermatol 1995; 133:6-12.
43. Rook AH, Gottlieb SL, Wolfe JT, et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol 1997; 107 (suppl 1):16-20.
44. Sinha AA, Heald P. Advances in the management of cutaneous T-cell lymphoma. Dermatol Clin 1998; 16:301-311.
45. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1089-1107.
46. Fox FE, Kubin M, Cassin M, et al. Retinoids synergize with interleukin2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cylokine Res 1999; 19:407-415.
47. Rook AH, Wood GS,Yoo EK, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94:902-908.
48. Duvic M, Rook A, Foss F, et al. A phase 2 open-label study of recombinant human interleukin-12 (RHIL-12) in patients with stage IA, IB or UA cutaneous T-cell lymphoma (CTCL). Proc Am Soc Clin Oncol 2000; 19:23a (Abstract #82).
49. Zackheim HS. Treatment of cutaneous T cell lymphoma with retinoids. Dermatologic Therapy 1998; 7:15-20.
50. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 34:1022-1029.
51. Duvic M, Chandraratna RAS. Retinoid receptor selectivity: importance and clinical application in dermatology and other diseases. Dermatologic Therapy 1998; 7:7-14.
52. Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996; 34:626-631.
53. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 1999; 17:3117-3121.
54. O'Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994; 84:733-738.
55. 389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am J Hematol 1998; 58:87-90.
56. Duvic M, Feasel AM, Schwanz CA, et al. Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entity. Clin Lymphoma 2000; 1:141-145.